Early detection of lung cancer can decrease lung cancer-related mortality by up to 20 percent1. We are committed to providing diagnostic solutions that support early identification of lung cancer.
With more than 1.6 million nodules detected incidentally each year2, clinical lung cancer risk assessment has become a critical component of managing patients. The Nodify XL2™ test is designed to help physicians stratify patients with incidental lung nodules by risk of malignancy.
We strive to transform lung cancer standards by equipping clinicians with the right information at the right time. Biodesix Lung Reflex® testing delivers integrated blood-based genomic and proteomic results within 72-hours, expediting time to treatment.